Abbott LaboratoriesABT
NYSE • Healthcare
$102.64
P/E
27.50
PEG
1.49
FCF Yield
4.1%
Rev Growth YoY
+4.4% YoY
Gross Margin
56.7%
Health Score
7/10
D/E Ratio
0.25
Confidence
MEDIUM
Business Snapshot
Abbott Laboratories is a diversified large-cap healthcare company operating across medical devices, diagnostics, nutrition, and established pharmaceuticals, with a market capitalisation of $179.95B. Its device and diagnostics segments span cardiovascular systems, continuous glucose monitoring (CGM), and point-of-care testing. At nearly $180B in market cap, Abbott sits firmly in large-cap territory and is one of the most widely held names in the healthcare sector.
Financial Health
**Score: 7/10** Abbott's balance sheet is notably conservative, with a debt/equity ratio of just 0.25x, indicating minimal leverage relative to equity. Free cash flow stands at a robust $7.33B (yielding 4.1% on the current market cap), providing significant financial flexibility...
Risk Assessment
- **EARNINGS QUALITY:** Earnings growth of -80.9% year-over-year despite positive revenue growth signals meaningful margin compression or one-time charges weighing on net income. - **VALUATION vs DCF:** The Python DCF fair value of $72.16 implies the current price of $102.64 is trading at a 42% premium to modelled intrinsic value, assuming 4.4% growth and 9.0% WACC. - **TECHNICAL DETERIORATION:** A confirmed death cross (50-day MA of $109.36 crossing below the 200-day MA of $124.14) signals sustained intermediate-term downward momentum, with the current price below both moving averages. - **EARNINGS BEATS:** Abbott beat analyst estimates in only 1 of 4 recent quarters, indicating a pattern of guidance misses that could weigh on near-term sentiment. - **PRICE PROXIMITY TO 52-WEEK LOW:** At $102.64, the stock is trading just 1.7% above its 52-week low of $100.88, reflecting persistent selling pressure over the past year. ---...